Bocom Intl released a report indicating that Beigene (06160.HK) continues to show a trend of increased product sales in the third quarter, with the market share of the core indications for Zebrutinib continuing to expand: the company's total revenue grew by 28.2% year-on-year to 1.002 billion USD. Adjusted non-GAAP operating profit was 65.63 million USD, achieving positive non-GAAP operating profit for two consecutive quarters.

The bank increased the target price for Beigene's listed in hong kong to 159 HKD. The bank stated that its catalysts are about to intensify, with a focus in the next 12 months on: approval for more indications like Terebrutinib 1LESCC and 1L GC in core developed markets such as Europe and the United States, and data reads from I/O combination therapy; initiation of two Phase III studies for the Bcl-2 inhibitor Sonrotoclax in 1H25, and more preliminary data reads for additional indications; initiation of the first Phase III clinical trial for BTK degraders in 1H25; and more candidates for solid tumors entering the clinical stage.